The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't-Reference-Cited by-同舟云学术

The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't

Published:2022-02 Issue:2 Volume:14 Page:91-94
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Malek Alexandre E¹^ORCID,Cornejo Paulette Pinargote¹,Daoud Nour¹,Alam Mohammad¹

Affiliation:

1. Department of Medicine, Division of Infectious Diseases, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2021-0235

Reference25 articles.

1. Commentary: SARS-CoV-2 vaccines and cancer patients

2. The National Comprehensive Cancer Network. NCCN: Cancer and COVID-19 vaccination (2021). www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v3-0.pdf?sfvrsn=b483da2b_60.

3. American Society of Clinical Oncology. COVID-19 vaccines & patients with cancer (2021). www.asco.org/asco-coronavirus-information/covid-19-vaccines-patients-cancer.

4. European Society for Medical Oncology. COVID-19 vaccination in cancer patients: ESMO statements (2021). www.esmo.org/covid-19-and-cancer/covid-19-vaccination.

5. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A survey on the attitude and willingness of Chinese cancer patients toward a COVID-19 booster vaccine;2024-04-19

2. WITHDRAWN: A Survey on the Attitude and Willingness of Chinese Cancer Patients toward a COVID-19 Booster Vaccine;Heliyon;2024-02

4. Celebrating the 15th anniversary of Immunotherapy: a reflection on 2022;Immunotherapy;2023-01

5. Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations;Therapeutic Advances in Medical Oncology;2023-01